Skip to main content
. 2020 Aug 27;10(8):e034626. doi: 10.1136/bmjopen-2019-034626

Figure 5.

Figure 5

Analysis of overall survival for patients with favourable risk (A), intermediate risk (B) and poor risk (C). Numbers in parentheses indicate 95% credible intervals. NIV_IPI, nivolumab plus ipilimumab; PAZ, pazopanib; PEM_AXI, pembrolizumab plus axitinib; SUN, sunitinib.